Create a free research account to view current pricing and place an order.
How does Retatrutide work in research models?
Retatrutide is a triple agonist acting through GLP, GIP, and glucagon receptor pathways. In addition to incretin-mediated satiety and glycemic signaling, glucagon receptor activity may support hepatic fatty-acid utilization and energy-expenditure signaling.
What is the half-life of Retatrutide?
Half-life: Approx. 6 days; investigational.
Clinical research references commonly describe a weekly profile with an approximate half-life around 6 days. Human PK remains investigational compared with approved incretin drugs; conservative escalation and accumulation awareness are important.
Research dosing reference
1-12 mg once weekly; conservative escalation is strongly preferred.
Dose interpretation (U-100 units)
| Target dose | U-100 units |
|---|---|
| 1 mg | 20 units |
| 2 mg | 40 units |
| 4 mg | 80 units |
| 8 mg | 160 units |
Units are concentration-specific - confirm against your actual reconstitution volume.
How is Retatrutide reconstituted?
| Vial | Preferred reconstitution | Final concentration |
|---|---|---|
| 10 mg | 2 mL BAC Water | 0.050 mg/unit |
| 15 mg | 2 mL BAC Water | 0.075 mg/unit |
| 20 mg | 2 mL BAC Water | 0.100 mg/unit |
| 30 mg | 3 mL BAC Water preferred for dissolution and simplified concentration interpretation | 0.100 mg/unit |
| 60 mg | 3 mL BAC Water preferred for dissolution and simplified concentration interpretation | 0.200 mg/unit |
Injection timing
Once weekly on a consistent day. Time of day is less important than consistency; choose timing that minimizes nausea disruption.
Beginner escalation
Start at the lowest practical exposure and hold each step long enough to evaluate GI tolerance before increasing.
Side-effect mitigation
Monitor nausea, reflux, constipation, reduced appetite, hydration status, fatigue, and delayed gastric emptying. Slow escalation and hydration/electrolytes are primary mitigation tools.
Stack compatibility
Avoid stacking overlapping incretin agonists unless intentionally structured and clinician supervised. Pathway contrast with GH-axis, mitochondrial, or lipolysis adjuncts is generally cleaner than incretin overlap.
Storage & stability
Lyophilized: refrigerated or controlled cool storage. Reconstituted: refrigerated, protected from heat/light, and handled aseptically.
Protocol duration & reassessment
Investigational triple-agonist protocols should use extended stabilization periods between increases. Reassess every 8-12 weeks due to accumulation potential and overlapping GLP/GIP/glucagon signaling effects.
Frequently asked questions
What is Retatrutide and how is it studied?
Retatrutide is a triple agonist acting through GLP, GIP, and glucagon receptor pathways. In addition to incretin-mediated satiety and glycemic signaling, glucagon receptor activity may support hepatic fatty-acid utilization and energy-expenditure signaling. Retatrutide is catalogued in the GLP / Metabolic group of this reference and is studied in laboratory and in-vitro models only.
What is known about the half-life of Retatrutide?
Reference half-life for Retatrutide: approx. 6 days; investigational. Published pharmacokinetic figures come from research and clinical-literature contexts and are listed here as reference values for laboratory work only, not as guidance for any person or animal. Every lot of Retatrutide is third-party tested to a 99%+ purity target, with identity confirmed by mass spectrometry and purity quantified by HPLC.
How is Retatrutide stored?
Lyophilized: refrigerated or controlled cool storage. Reconstituted: refrigerated, protected from heat/light, and handled aseptically. Lyophilized research peptides are generally kept cold, dry, and away from light, and reconstituted solutions are labeled with concentration and date. Follow the storage conditions documented for the specific lot you receive.
How is Retatrutide reconstituted for laboratory work?
The reference reconstitution for the 10 mg vial is 2 mL BAC Water, which gives a concentration of about 5 mg/mL. Concentration equals peptide mass divided by diluent volume, so adding more liquid lowers the concentration. Add diluent slowly down the vial wall, swirl rather than shake, and confirm the arithmetic before preparing any research solution.
Is Retatrutide FDA approved?
No. The research-grade Retatrutide described here is an investigational, research-use-only material and is not an FDA-approved drug product. Where an approved pharmaceutical form of a compound exists, it is a separate prescription product. This reference is not medical advice, and the material is not for human or animal consumption.
All research reference · Research guides
External references: Peptide (Wikipedia) · U.S. Food and Drug Administration